Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of CHIKV VLP vaccine in children aged 1 to under 12 years
2025-000141-10Phase 3
- Sponsor
- Bavarian Nordic
- Start
- Jun 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Chikungunya (CHIKV) comparing CHIKV VLP vaccine with Placebo (2 arms). Primary endpoint: Day 22 anti-CHIKV serum neutralizing antibody seroresponse rate.
02
Drugs
CHIKV VLP vaccine
03
Conditions
Chikungunya (CHIKV)
Beyond the preview
Go deeper on 2025-000141-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-000141-10.